Back to School: How biopharma can reboot drug development. Access exclusive analysis here

anti-CD11a (hu1124): Began Phase I/II trial

Genentech Inc. (DNA), South San Francisco, Calif.

Read the full 75 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE